Skip to main content
. Author manuscript; available in PMC: 2012 Jun 12.
Published in final edited form as: Psychopharmacology (Berl). 2007 Dec 27;197(1):157–168. doi: 10.1007/s00213-007-1020-8

Figure 2.

Figure 2

Selected peak ratings on the Drug-effects Questionnaire and ratings of marijuana craving averaged across the session as a function of THC (60 mg/day), lofexidine (2.4 mg/day) and the THC (60 mg) and lofexidine (2.4 mg/day) combination during marijuana abstinence (inpatient days 5–6). Asterisks indicate a significant difference between medication and placebo (* p < 0.05; ** p < 0.01). Error bars represent ± standard error of the mean (SEM).